Malaria future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
YazanDaaboul (talk | contribs) |
||
| Line 2: | Line 2: | ||
{{Malaria}} | {{Malaria}} | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
===Anti-Malaria Vaccine=== | |||
In October 2005, Malaria Vaccine Initiative PATH (MVI/PATH) partnered with Glaxosmithkline, a pharmaceutical company, to develop an anti-malaria vaccine, using a grant by Bill & Melinda Gates Foundation. | In October 2005, Malaria Vaccine Initiative PATH (MVI/PATH) partnered with Glaxosmithkline, a pharmaceutical company, to develop an anti-malaria vaccine, using a grant by Bill & Melinda Gates Foundation. | ||
The vaccine, called "GSK RTS,S/AS01" was administered with other vaccines included in Expanded Programme on Immunization (EPI). It includes 2 proteins: RTS and S. It is produced by ''S. cerevisiae'' species. The project ended in December 2014 with the publishing of two phase 3 trial reports in 2011 and 2012. The "RTS,S/AS01" vaccine affects the pre-erythrocytic stage of "P. falciparum" in young (5-17 months old) African children.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> The authors concluded in 2011, after 12 months of follow-up, that the candidate vaccine has an efficacy against clinical and severe malaria of 55.8% and 47.3%, respectively.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> In cases of severe malaria in children between 6 to 12 weeks of age, the efficacy was less. In 2012, infants 6-12 weeks of age were enrolled. The study showed that the vaccine efficacy against all clinical malaria was 32.9% and against severe malaria was 29%.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> | The vaccine, called "GSK RTS,S/AS01" was administered with other vaccines included in Expanded Programme on Immunization (EPI). It includes 2 proteins: RTS and S. It is produced by ''S. cerevisiae'' species. The project ended in December 2014 with the publishing of two phase 3 trial reports in 2011 and 2012. The "RTS,S/AS01" vaccine affects the pre-erythrocytic stage of "P. falciparum" in young (5-17 months old) African children.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> The authors concluded in 2011, after 12 months of follow-up, that the candidate vaccine has an efficacy against clinical and severe malaria of 55.8% and 47.3%, respectively.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> In cases of severe malaria in children between 6 to 12 weeks of age, the efficacy was less. In 2012, infants 6-12 weeks of age were enrolled. The study showed that the vaccine efficacy against all clinical malaria was 32.9% and against severe malaria was 29%.<ref name="pmid23136909">{{cite journal| author=RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG et al.| title=A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. | journal=N Engl J Med | year= 2012 | volume= 367 | issue= 24 | pages= 2284-95 | pmid=23136909 | doi=10.1056/NEJMoa1208394 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23136909 }} </ref> | ||
==References== | ==References== | ||
Revision as of 03:24, 25 July 2014
|
Malaria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Malaria future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Malaria future or investigational therapies |
|
Risk calculators and risk factors for Malaria future or investigational therapies |
Future or Investigational Therapies
Anti-Malaria Vaccine
In October 2005, Malaria Vaccine Initiative PATH (MVI/PATH) partnered with Glaxosmithkline, a pharmaceutical company, to develop an anti-malaria vaccine, using a grant by Bill & Melinda Gates Foundation.
The vaccine, called "GSK RTS,S/AS01" was administered with other vaccines included in Expanded Programme on Immunization (EPI). It includes 2 proteins: RTS and S. It is produced by S. cerevisiae species. The project ended in December 2014 with the publishing of two phase 3 trial reports in 2011 and 2012. The "RTS,S/AS01" vaccine affects the pre-erythrocytic stage of "P. falciparum" in young (5-17 months old) African children.[1] The authors concluded in 2011, after 12 months of follow-up, that the candidate vaccine has an efficacy against clinical and severe malaria of 55.8% and 47.3%, respectively.[1] In cases of severe malaria in children between 6 to 12 weeks of age, the efficacy was less. In 2012, infants 6-12 weeks of age were enrolled. The study showed that the vaccine efficacy against all clinical malaria was 32.9% and against severe malaria was 29%.[1]
References
- ↑ 1.0 1.1 1.2 RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG; et al. (2012). "A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants". N Engl J Med. 367 (24): 2284–95. doi:10.1056/NEJMoa1208394. PMID 23136909.